Payment overview · 2025
General Payments
$326.18
12 reported records · 7 companies
Healthcare provider profile · identity verified
Belinda Maples, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ATHENS, AL · NPI 1245223684
Verified facts
What the public records show
CMS Open Payments records show Belinda Maples, M.D. received $326.18 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 42.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.35 | 42.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $55.11 | 16.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.13 | 12.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.76 | 10.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.28 | 6.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.49 | 6.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.06 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $326.18 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $123.84 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $55.11 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 26 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 169 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
169 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
77 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
79 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 533 | 164 |
| Gabapentin | Gabapentin | 342 | 115 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 340 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 91 |
| Lisinopril | Lisinopril | 278 | 95 |
| Omeprazole | Omeprazole | 266 | 79 |
| Famotidine | Famotidine | 257 | 91 |
| Metformin Hcl | Metformin Hcl | 257 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 257 | 86 |
| Alprazolam | Alprazolam | 239 | 35 |
| Simvastatin | Simvastatin | 197 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 193 | 62 |
| Losartan Potassium | Losartan Potassium | 191 | 63 |
| Montelukast Sodium | Montelukast Sodium | 191 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 52 |
| Clonazepam | Clonazepam | 175 | 31 |
| Farxiga | Dapagliflozin Propanediol | 169 | 41 |
| Eliquis | Apixaban | 155 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 52 |
| Sertraline Hcl | Sertraline Hcl | 149 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 45 |
| Trazodone Hcl | Trazodone Hcl | 139 | 43 |
| Meloxicam | Meloxicam | 135 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 37 |
| Carvedilol | Carvedilol | 132 | 41 |
| Tramadol Hcl | Tramadol Hcl | 131 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 129 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 127 | 40 |
| Spironolactone | Spironolactone | 121 | 43 |
| Furosemide | Furosemide | 102 | 43 |
| Alendronate Sodium | Alendronate Sodium | 99 | 28 |
| Mounjaro | Tirzepatide | 89 | 19 |
| Ezetimibe | Ezetimibe | 87 | 28 |
| Prednisone | Prednisone | 84 | 69 |
| Sucralfate | Sucralfate | 84 | 33 |
| Allopurinol | Allopurinol | 82 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 81 | 22 |
| Rybelsus | Semaglutide | 79 | 17 |
| Entresto | Sacubitril/Valsartan | 77 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 24 |
| Topiramate | Topiramate | 68 | 20 |
| Ozempic | Semaglutide | 67 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 17 |
| Mirtazapine | Mirtazapine | 60 | 22 |
| Clonidine Hcl | Clonidine Hcl | 58 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 21 |
| Trulicity | Dulaglutide | 57 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 19 |
| Jardiance | Empagliflozin | 56 | 12 |
| Fluconazole | Fluconazole | 55 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 17 |
| Glimepiride | Glimepiride | 51 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 22 |
| Methocarbamol | Methocarbamol | 50 | 21 |
| Atenolol | Atenolol | 47 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 14 |
| Donepezil Hcl | Donepezil Hcl | 44 | 16 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 35 |
| Azithromycin | Azithromycin | 36 | 34 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 12 |
| Finasteride | Finasteride | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | 11 |
| Glipizide | Glipizide | 32 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 14 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | 12 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 26 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 11 |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Prolia | Denosumab | 19 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Latanoprost | Latanoprost | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $326.18 · 12 records | Novo Nordisk Inc | ABRYSVO, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, LEQVIO, Ozempic, PREVNAR 20, TZIELD, VYNDAMAX, Wegovy, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error